Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl Matt Burke2019-12-18T21:30:52-05:00December 18, 2019| Read More
Cullinan Co-Founder Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy Cullinan Co-Founder Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy Kristen Laguerre2019-02-27T09:42:53-05:00February 27, 2019| Read More
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor root2019-02-05T18:07:22-05:00February 5, 2019| Read More
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute Kristen Laguerre2019-02-05T18:07:53-05:00January 30, 2019| Read More
